NCT01543841|Completed
Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood
A Laboratory Evaluation of Tie-2 Expressing Monocytes (TEMs) in Healthy Volunteers and Patients With Advanced Cancer
Loading search results
A Laboratory Evaluation of Tie-2 Expressing Monocytes (TEMs) in Healthy Volunteers and Patients With Advanced Cancer
Sponsor study identifier
observational
20
1 country
1
Study Start
August 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2014
Actual (reported)Study Completion
January 2014
Actual (reported)Tie-2 expressing monocytes (TEMs) are a specific type of blood cell that are present in healthy individuals and in people with cancer. These cells may play a role in the growth of blood vessels (veins/arteries), and may be particularly important in the growth of blood vessels that supply tumours. Understanding how these cells work may therefore help researchers to develop cancer treatments that starve tumors of their blood supply. This research study involves an analysis of the behaviour of blood cells in response to different drugs in a test tube. The goal is to develop tests that can then be used to monitor patients treated with drugs that target blood vessel growth.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2014
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 19, 2012
Actual (reported)March 5, 2012
Actual (reported)August 2012
Date type not reportedThis date has not been verified as actual or estimated.
January 2014
Actual (reported)January 2014
Actual (reported)Characterize the in vitro response of circulating myeloid cells to angiopoeitins-1 and 2 (ANG1 and 2) in the presence or absence of pharmacologic inhibitors
This is an observational correlative laboratory protocol in which one tube of blood from healthy volunteers and cancer patients will be collected to perform in vitro stimulation of TEMs with ANG1 and 2 and flow cytometry analysis, which could serve as a biomarker for future ANG directed therapies. The results of this study will contribute to an improved understanding of ANG-TIE2 signaling in TEMs. Furthermore, this study will contribute directly to the development and optimization of protocols that will be applied a separate Phase I NCI trial of AMG 386 and temsirolimus.
1 year
Develop and optimize flow cytometry analyses
1 year
Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (\~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
Eligible volunteers will have one tube of whole blood (\~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
Patients with advanced cancer attending the Phase I clinic and healthy staff at the Princess Margaret Hospital
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
One tube of whole blood
Lillian Siu, MD
Princess Margaret Hospital, Canada
20 participants (actual enrollment reported by the registry).
First Submitted
January 19, 2012
First Posted
March 5, 2012
Study Start
August 2012
Date type not reportedThis date has not been verified as actual or estimated.
Effects of Mode of Administration of Soluble Fibre Blend on Glycemia, Appetite & Sensory Parameters
Contact the study team to confirm eligibility.
Primary Completion
January 2014
Actual (reported)Study Completion
January 2014
Actual (reported)Last Updated
February 15, 2019
Record last verified: 2019-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: